Search Results
289 Results for 'Therapeutics & Vaccines'
PAGE 3 OF 12
Technology
Syndecan Peptides And Polypeptides As Inhibitors Of Vegfr2 And Vla-4
Peptides derived from amino acid residues 210 to 240 of human syndecan 1 and methods of use of such peptides are described. These peptides can inhibit activation of α4β1 integrin (also known as very...
Learn More
Learn More
Alan Rapraeger, Oisun Jung | P150222US02
Technology
Inhibitors Of Collagen Prolyl 4-Hydroxylase
The invention provides biheteroaryl dicarboxylates and esters, and salts thereof which are useful generally as modulators of CP4H activity, more particularly as inhibitors of CP4H, or further as chemi...
Learn More
Learn More
Ronald Raines, James Vasta | P150092US02
Technology
Influenza Virus Replication By Inhibiting Microrna Lec7c Binding To Influenza Viral Crna And Mrna
A vector, composition and method to improve influenza virus replication by inhibiting miRNA lec-7C binding to influenza virus mRNA and/or cRNA.
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P150345US02
Technology
Generation Of Infectious Influenza Viruses From Virus-Like Particles
Compositions and methods to prepare influenza virus-like particles (VLPs) are provided.
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann | P150373US02
Technology
Method Of Synthesizing 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol
A method of making 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol. The method includes the steps of condensing a bicyclic ketone with an allylic phosphine oxide to produce a protected 19-nor-preg...
Learn More
Learn More
Hector DeLuca, Sumithra Gowlugari, Rafal Sicinski | P02396US
Technology
1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D Compounds And Methods Of Making And Treatm
Disclosed are 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds, pharmaceutical compositions, and methods of making and treatment thereof. The compounds are generally directed to biol...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame, Agnieszka Glebocka, Rafal Sicinski | P06338US
Technology
Anti-microbial Agents
Antimicrobial agents that can serve as replacements to conventional pharmaceutical antibiotics are disclosed. The antimicrobial agents comprise conjugatively transmissible plasmids that kill targeted ...
Learn More
Learn More
Marcin Filutowicz | P04023US
Technology
Methods And Compositions For Phosphate Binding
The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administ...
Learn More
Learn More
Hector DeLuca, Katarzyna Barycka, Lori Plum, Julia Zella, Margaret Clagett-Dame | P08110US
Technology
Use Of Neuropeptides For Ligament, Cartilage, And Bone Healing
Disclosed are a method and a corresponding pharmaceutical composition for treating damaged cartilage and subchondral bone. Neurogenic compounds in general and neuropeptides in particular have been fou...
Learn More
Learn More
Ray Vanderby, Kelley Grorud | P05193US
Technology
2-methylene-19-nor-20(s)-1 Alpha-hydroxy-bis-homo-pregnacalciferol In Crystalline Form
A method of purifying 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacaciferol to obtain 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form. The method includes th...
Learn More
Learn More
Hector DeLuca, James Thoden, Hazel Holden, Margaret Clagett-Dame, Pawel Grzywacz, Sumithra Gowlugari | P02175US
Technology
Once-A-Week Administration Of 25-Hydroxy Vitamin D3 To Sustain Elevated Steady-State Pharmacokinetic Blood Concentration
An oral dosage form comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and ...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame | P08138US02
Technology
High-Potency Botulinum Toxin Formulations
The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and h...
Learn More
Learn More
Gary Borodic | P08444US01
Technology
2-methylene-20(21)-dehydro-19-nor-vitamin D Analogs
This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This comp...
Learn More
Learn More
Hector DeLuca, Bulli Padmaja Tadi, Lori Plum, Margaret Clagett-Dame | P08364US
Technology
2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin D Analogs
This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1α, 25-dihydroxyvitamin D3, and pharmaceutical u...
Learn More
Learn More
Hector DeLuca, Bulli Padmaja Tadi, Lori Plum, Margaret Clagett-Dame | P08365US
Technology
2-methylene-(20s,25s)-19,26-dinor-vitamin D Analogs
This invention discloses 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,26-dinor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This comp...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame, Grazia Chiellini, Pawel Grzywacz | P08089US
Technology
2-methylene-(20s,25r)-19,26-dinor-vitamin D Analogs
This invention discloses 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25R)-19,26-dinor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This comp...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame, Grazia Chiellini, Pawel Grzywacz | P08090US
Technology
2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D Analogs
This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20-methyl-1α-hydroxy-19,24,25,26,27-pentanor-vitamin D3, and pharmaceutical uses...
Learn More
Learn More
Hector DeLuca, Lori Plum, Agnieszka Glebocka, Margaret Clagett-Dame, Rafal Sicinski | P08106US
Technology
Reversible Natural Product Glycosyltransferase-catalyzed Reactions, Compounds And Related Methods
The present invention relates to methods of use of glycosyltransferases and related compounds. The invention exploits the reversibility of glycosyltransferases to generate new sugars, unnatural biomol...
Learn More
Learn More
Jon Thorson, Byron Griffith, Changsheng Zhang | P06427US
Technology
2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin D Analogs
This invention discloses 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,27-dinor-(22E)-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefo...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Grazia Chiellini, Pawel Grzywacz | P07107US
Technology
19,26,27-trinor-1alpha,25-dihydroxyvitamin D3 Compounds
This invention relates to vitamin D compounds, and more particularly to 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds such as 2α-methyl-19,26,27-trinor-(20S)-1α,25-dihydroxyvitamin D3 (“P...
Learn More
Learn More
Hector DeLuca, Lori Plum, Pawel Grzywacz, Margaret Clagett-Dame | P05370US
Technology
Use Of Botulinum Toxin For The Treatment Of Hypervolemic Lip Deformity (lip Ectropion)
The present invention uses pharmaceutical preparations of Botulinum toxin to induce neurogenic atrophy to alter muscle volume and subsequently, facial contour. Reduction in lip volume is accomplished ...
Learn More
Learn More
Gary Borodic | P05407US
Technology
17,20(z)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(Z)-dehydro vitamin D analogs, and specifically 17(Z)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P06097US
Technology
17,20(e)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P06117US
Technology
2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol And Its Uses
This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibit...
Learn More
Learn More
Hector DeLuca, Lori Plum, Rafal Sicinski, Margaret Clagett-Dame | P05163US
Technology
Selection Of Patients With Increased Responsiveness To Botulinum Toxin
Botulinum toxin has been shown to be useful for the treatment of pain when administered for cervical dystonia. Given efficacy for pain relief in regional dystonia, further expanded applications have i...
Learn More
Learn More
Gary Borodic | P05052US